Inhibition of NF-κB with BAY 11–7082 reduced both tumor growth and Ki-67 expression, whereas co-treatment with BAY 11–7082 and the ferroptosis-inducer erastin reversed these effects. Here, NFKB1 is linked to neoplasm.